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Abstract
Background: Pyronaridine (PN) and chloroquine (CQ) are structurally related anti-malarial drugs with primarily the
same mode of action. However, PN is effective against several multidrug-resistant lines of Plasmodium falciparum,
including CQ resistant lines, suggestive of important operational differences between the two drugs.
Methods: Synchronized trophozoite stage cultures of P. falciparum strain K1 (CQ resistant) were exposed to 50%
inhibitory concentrations (IC50) of PN and CQ, and parasites were harvested from culture after 4 and 24 hours
exposure. Global transcriptional changes effected by drug treatment were investigated using DNA microarrays.
Results: After a 4 h drug exposure, PN induced a greater degree of transcriptional perturbation (61 differentially
expressed features) than CQ (10 features). More genes were found to respond to 24 h treatments with both drugs,
and 461 features were found to be significantly responsive to one or both drugs across all treatment conditions.
Filtering was employed to remove features unrelated to primary drug action, specifically features representing
genes developmentally regulated, secondary stress/death related processes and sexual stage development. The
only significant gene ontologies represented among the 46 remaining features after filtering relate to host
exported proteins from multi-gene families.
Conclusions: The malaria parasite’s molecular responses to PN and CQ treatment are similar in terms of the genes
and pathways affected. However, PN appears to exert a more rapid response than CQ. The faster action of PN may
explain why PN is more efficacious than CQ, particularly against CQ resistant isolates. In agreement with several
other microarray studies of drug action on the parasite, it is not possible, however, to discern mechanism of drug
action from the drug-responsive genes.
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Background
Malaria is a parasitic disease accounting for almost one
million deaths per year, mostly among children in Sub-
Saharan Africa, Asia, Central and South America [1].
During the last two decades, the incidence of malaria
has remained unacceptably high. A major factor in the
continuing burden of malaria is the spread of parasites
resistant to front-line anti-malarials such as chloroquine
and sulphadoxine/pyrimethamine [2], and perhaps in
the near future, artemisinin [3]. New anti-malarial drugs
with different modes of action are needed to overcome
drug-resistant parasites.
Pyronaridine (PN) is a Mannich base 9-anilinoacridine
structurally related to chloroquine (CQ) (Figure 1). PN
was one of the earliest synthetic anti-malarial drugs first
developed in China in the late 1970s [4,5]. It is a highly
effective blood schizonticidal agent, even against multi-
drug-resistant lines of Plasmodium falciparum [6,7]. In
addition to its schizonticidal activity, it has been shown
to possess an in vitro gametocytocidal effect in P. falci-
parum [8]. It is also effective against Plasmodium vivax
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[10]. Furthermore, it has been demonstrated to be effec-
tive in Phase III human trials for treating P. falciparum
malaria in SE Asia and Africa [11]. Despite extensive
reports of its highly potent anti-malarial activity, few
studies have been conducted to determine the drug’s
mechanism of action. Based on the fact that 9-anilinoa-
cridines are potent anti-cancer drugs that target DNA
topoisomerase II (TOPO II), it was proposed that PN
acted in a similar manner by inhibiting parasite TOPO
II [12]. However, it was later shown that parasite TOPO
II inhibition by PN is insignificant in situ [13]. Auparak-
kitanon et al [14] later demonstrated that the primary
mode of action of PN is similar to that of CQ, namely
inhibition of a-haematin formation, enhanced haematin-
induced red blood cell lysis and interference with glu-
tathione-dependent heme degradation. The hypothesis
of shared mode of action is further supported by the
electron microscopic examination of PN-treated P. falci-
parum from an infected Aotus (owl monkey) [15], which
revealed that like CQ, the earliest morphological change
induced by PN is the appearance of abnormal vesicles in
the food vacuole. Despite the hypothesized similarity of
drug action, CQ-resistant field isolates are not cross-
resistant to PN, implying that there are some important
pharmacological differences between the two drugs [7].
From the available information, it is not known whether
the differences between CQ and PN efficacy exist
because of differences in mode of action, or differences
in cellular resistance mechanisms, e.g., to what extent
PN is a substrate for PfCRT-mediated transport com-
pared with CQ.
In this study, a better understanding of the mechan-
ism of action of PN was sought, including the reason
why PN is so effective against CQ-resistant parasites,
despite the proposed similarity of drug action for PN
and CQ. To help answer these questions, DNA microar-
rays were employed to measure global gene expression
changes of a CQ-resistant strain of P. falciparum in
response to individual 50% inhibitory concentrations of
PN and CQ. There is extensive overlap in the genes
affected by both drugs, although PN appears to elicit a
more rapid response by the parasite than CQ. The
majority of genes changing expression in response to
both drugs are likely to be the result of developmental
arrest and secondary stress/death related cellular pro-
cesses; hence, there are very few genes which can be
considered as specifically PN and CQ drug responsive.
Methods
Microarray construction
DNA microarrays were used containing 8,088 70-mer
oligonucleotide probes representing the majority of
annotated open reading frames (ORF) as listed in Plas-
moDB 4.4 [16]. The oligo probes were printed on poly-
lysine coated glass slides using a new generation ultra
fast, linear servo driven DeRisi microarrayer controlled
by an ArrayMaker software [17].
Parasite culture and drug treatment
K1 (chloroquine-resistant) strain of P. falciparum was
used for all experiments. This strain was selected since
it is representative of the CQ-resistant parasite popula-
tion where PN is likely to be employed as an anti-malar-
ial in the future. Moreover, PN resistant parasites have
not yet been isolated from the field, nor are there any
reports of laboratory resistance for P. falciparum. Para-
sites were cultured in vitro as described previously in
[18]. Culture synchronization was obtained by lysing
mature parasites with 5% sorbitol for two consecutive
cell cycles [19]. Pyronaridine (PN) (a gift from Simon
Croft, London School of Hygiene and Tropical Medi-
cine, UK) and chloroquine (CQ) (Sigma-Aldrich) were
dissolved in dimethylsulfoxide (DMSO). The 50% inhibi-
tory concentrations (IC50) of each drug against K1 para-
sites were determined by the (
3H)-hypoxanthine
incorporation method [20] with minor modifications.
The IC50 values from triplicate biological replicates
(with three technical replicates in each) for PN and CQ
were 11 ± 2.0 nM and 276 ± 38 nM respectively, con-
firming the PN-sensitive and CQ-resistant phenotypes
of the K1 strain parasites. The IC50 values determined
for the K1 strain are very similar to those reported pre-
viously [6].
For DNA microarray experiments, a synchronized cul-
ture of early trophozoite parasites (22-24 h post-inva-
sion) was treated with the IC50 concentration of each
drug (11 nM for PN, and 280 nM for CQ), and the final
concentration of DMSO was 0.1% (v/v). For each treat-
ment, three culture plates (90 × 15 mm) were estab-
lished, each containing 1.25% haematocrit and 15-20%
parasitaemia in a total volume of 17 ml. The control
was a parasite culture (also synchronized and at the
same stage as those used for drug treatment) containing
0.1% (v/v) DMSO, but lacking drug. Parasites were
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Figure 1 Chemical structures of Pyronaridine (PN) and
Chloroquine (CQ).
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time point, parasites were harvested and liberated from
erythrocytes by saponin lysis. Drug treatment was per-
formed on 3-6 replicates. For identification of develop-
mentally-regulated transcripts, 3 biological replicates of
synchronized cultures of parasites at ring (8-10 h post-
invasion), trophozoite (22-24 h post-invasion) and schi-
zont (38-40 h post-invasion) stages were harvested for
total RNA extraction.
Total RNA extraction and cDNA labeling
Total RNA was extracted from parasites using TRIzol
reagent (Invitrogen) in accordance with the manufac-
turer’s recommendations. For each cDNA labeling reac-
tion, 10-15 μg of total RNA were annealed with 5 μgo f
oligo (dT)21 and reverse transcribed to produce ami-
noallyl-dUTP(Ambion)-containing cDNA using Strata-
script™ reverse transcriptase (Stratagene). The cDNA
from the drug-treated RNA preparations was then
labelled with monoreactive Cy5, while the cDNA from
control untreated RNA samples was labelled with Cy3.
To identify transcripts related to parasite development,
cDNA obtained from synchronized parasites at ring, tro-
phozoite and schizont stages were individually labelled
with Cy5. A pooled reference RNA was made from the
three stage samples mixed in equal proportions. The
pooled reference cDNA was labelled with Cy3.
Microarray hybridization
Purified Cy3- and Cy5-labelled cDNA were mixed in a
Short Oligo Hybridization Solution (Corning Inc.), and
hybridized to P. falciparum spotted 70-mer oligo micro-
arrays for 16-18 h at 45°C. Arrays were washed at room
temperature in a solution of 2× SSC 1× (Sodium Saline
Citrate) containing 0.2% SDS, and then in 0.1× SSC.
Then arrays were dried by centrifugation and immedi-
ately scanned using a ScanArray 4000B microarray scan-
ner (Packard/Perkin Elmer, USA) or a GenePix Pro
4000 scanner according to the manufacturer’si n s t r u c -
tions. Images were analysed using ScanAlyze software
[21] or Genepix Pro to obtain hybridization intensity
outputs.
Microarray data analysis
T h er a wi n t e n s i t yd a t af r o mb o t hc h a n n e l sw e r ep r e -
processed as described previously in [22], and normal-
ized within arrays using the global lowess algorithm
and across replicate arrays from the same experiment
in the Aroma package [23] run in R 2.8.1 project
environment [24]. All microarray data and details of
experimental design were submitted to the NCBI Gene
Expression Omnibus (GEO) database and are available
under series accession numbers GSE31109, GSE30867
and GSE30869.
After normalization, array features with less than three
experimental values were excluded from further ana-
lyses. For study of developmentally regulated transcripts,
lists were made of the average normalized log2 change
in expression of all retained microarray features for the
K1 ring, trophozoite and schizont stages (4625, 4651,
and 4640 features, respectively). These lists were then
compared with measurements for the corresponding
microarray features from 46 time-points across the HB3
strain parasite life cycle as reported in [25] by calcula-
tion of global Pearson correlation coefficients for each
K1 developmental sample and HB3 time-point.
Differentially expressed genes were identified from
each drug treatment time-point using the Significance
Analysis of Microarrays (SAM) programme, Excel plug-
in version 3.05 [26]. Array features showing both a q-
value of less than 5% and an expression ratio of ≥ 1.8
fold in either direction were considered as being differ-
entially expressed (Additional file 1). The SAM algo-
rithm uses nonparametric statistics to calculate q-values.
The q-value for each feature is a measure of the positive
false discovery rate (FDR), or how many features show-
ing the same or greater level of differential expression
are actually false positives [27]. Heatmap analysis of
selected normalized data from array features with a sig-
nificant change in expression under one or more of the
drug treatment conditions was performed using the
NeatMap package [28], in which rows (average normal-
ized log2 change in gene expression) were clustered
using the nMDS algorithm and columns (drug treatment
condition) were clustered by hierarchical average link-
age. Gene ontology enrichment analysis of the PN/CQ
responsive genes was performed using the GOEAST
web tool with default parameters [29]. Data manage-
ment (filtering of gene lists) and calculation of Pearson
correlation coefficients was carried out using Microsoft
Excel 2007.
Statistical testing of the overlap of array features com-
mon to different drug treatments was performed using a
Monte Carlo simulation method [30]. The simulation
was performed to determine the null distribution of
overlapping features occurring by chance among ran-
dom selections of features. The simulation generated
models of possible results by randomly selecting two dif-
ferent sets of features assumed to be the results of drug
treatments. Every instance of feature overlap was tallied
yielding distributions of possible outcome values. The
model was constructed by randomly selecting features
with replacement from the pool of 6203 independent
features to reconstruct the subsets of features showing
significant responses to PN (297) and CQ (205) drug
treatments. The number of intersecting features between
the two subsets was observed and tallied. The model is
defined as thus:
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ber of features and |S|=r, the number of features in
the subset S. S corresponds to a set of features chosen
randomly (without replacement) from A using uniform
distribution. Equivalently, this random process is
described using the shorthand S ←
N
r

.L e tK be the
total number of simulations. The Monte Carlo simula-
tion is described as:
for i =1t oK:
S1 ←
N
r1

S2 ←
N
r2

y(i) = S1 ∩ S2
Note that y(i) is a possible outcome of the experiment.
Let Y be a random variable representing the intersection
between S1a n dS2. Let K be the total number of simu-
lations. The probability of each possible intersection
event can be calculated by:
P(y = m)=
K 
j=1
j
 y(j)=m
I nt h eP N / C QM o n t eC a r l os i m u l a t i o n ,K =1×1 0
6;
N = 6203; |S1| = 297; and |S2| = 205 respectively. The
simulation was performed using a custom computer
script in the Ruby interpreter programme (Additional
file 2).
Results
Experimental design for comparative transcriptomic
profiling
The goal of this study was to identify global transcrip-
tional changes induced by PN and CQ in a CQ-resistant
strain of P. falciparum (K1). Synchronized cultures in
early trophozoite stages (22-24 h post invasion) were sub-
jected to IC50 concentrations of PN (11 nM) and CQ
(280 nM) for 4 and 24 h. IC50 drug treatments were used
since previous studies of CQ transcriptional response
using lower effective drug concentrations did not reveal
any drug-induced transcriptional changes [31]. Conver-
sely, very high drug concentrations can lead to develop-
mental arrest which confounds analysis of the drug
response (see below). Preliminary study with 30 min drug
exposures did not reveal any significant changes in
expression for either PN or CQ (data not shown). The 4
h time point was chosen to represent an ‘early’ response
to the drug in which we could be reasonably confident of
detecting some significant changes in expression. Impor-
tantly, the 4 h time point is also physiologically relevant
with respect to pharmacokinetics, since the time taken
for PN and CQ to reach their maximum plasma concen-
trations in patients administered with the drugs are 2-3 h
for PN [32] and 2-6 h for CQ [33]. The 24 h time point
was regarded as a ‘late’ drug response after which para-
sites had passed through the schizont stage, which is
known to be susceptible to PN and CQ action.
To gauge the global drug-induced transcriptomic
changes, DNA microarray experiments were performed
in which cDNA samples from drug-treated and non-
treated control cultures from each time point were
labelled with different cyanine dyes, mixed and hybri-
dized to the same microarray. In total, the dataset com-
prised nine microarray hybridizations each for PN and
CQ.
Comparison of PN and CQ transcriptional responses
In total, 297 and 205 microarray features were differen-
tially expressed under PN and CQ, respectively. There is
an overlap of 40 features which show significant changes
in expression to both drugs (Additional file 3). To test
whether this overlap is significant, a Monte Carlo simu-
lation was performed to discover the null distribution of
overlap occurring by chance for two feature lists with
the corresponding number of features made randomly
from the total of 6203 features that give robust signals
(three or more experimental values) in all PN and CQ
microarray experiments. The simulation shows that the
PN and CQ overlap is highly significant (p ≤ 1×1 0
-6),
indicating a significant similarity between the two
responses. To determine the biological significance of
the overlap between PN and CQ responsive features, the
254 significant features responsive to 24 h exposure of
Pyrimethamine, an antifolate drug with a different mode
of action [34] in the same K1 parasite strain were com-
pared with the PN and CQ responsive features. The
number of overlaps in each case was not significant (8
overlapping features for Pyrimethamine/CQ and 9 for
Pyrimethamine/PN; Additional file 3).
To compare the global transcriptional responses of
parasites to PN and CQ after different periods of expo-
sure, clustering and heatmap analyses were performed
on the 461 features showing significant differential
expression under at least one drug treatment (Figure 2).
The overall transcriptional response patterns of the PN
4 h, PN 24 h and CQ 24 h treatments are similar to one
another, which are confirmed by the global Pearson cor-
relations (Table 1). The overall change in gene expres-
sion is more modest after 4 h CQ exposure compared
with the others. In terms of significant differentially
expressed features, far fewer were found after CQ 4 h
exposure (10) than other treatments (61, 239 and 195
for PN 4 h, PN 24 h and CQ 24 h, respectively; Addi-
tional file 1).
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expression after drug treatment were identified, it
should be appreciated that drugs typically induce cell
cycle arrest, or delay before cell killing, leading to differ-
ences in cell stages between drug-treated and control
cultures. During normal growth, parasite stages show
markedly different gene expression profiles from one
another [25,35], and so the gene expression profile of
drug-treated parasites will likely differ from control
untreated parasites in part because of drug-induced
developmental delay. Different anti-malarial drugs
induce cell cycle arrest to different extents; for example,
lethal concentrations of antifolates do not induce mor-
phological arrest [36]. On the other hand, the develop-
mental arrest induced by cytostatic drugs such as DL-a-
difluoromethylornithine necessitate complex experimen-
tal designs employing multiple time-points of drug-trea-
ted and control cultures in order to correct for
transcriptional changes relating only to differences in
cell stage [37].
To identify the developmentally regulated genes,
which could confound identification of PN and CQ-
responsive genes, RNA samples from drug-free synchro-
nized cultures from ring, trophozoite, and schizont
stages were individually labelled and hybridized with a
pooled sample from the three stages. The data from this
experiment were used to compare the developmental
profile of the K1 strain with the high-resolution data for
the HB3 strain (Additional file 4). The peak of Pearson
correlation between the K1 trophozoite culture sample
(estimated age 22-24 h post infection) and HB3 is maxi-
mal at HB3 time-points 20-24 h (Figure 3), indicating a
high concordance between the two strains in terms of
developmentally regulated transcripts.
After 4 h drug treatment, > 90% of parasites were at the
trophozoite stage, while after 24 h drug treatment para-
sites were at schizont and early ring stages. Therefore,
microarray features showing developmental change in
the HB3 dataset (1.8 fold or greater change in expres-
sion) were filtered out from the lists of features differen-
tially expressed under drug treatment. For the 4 h drug
treatments, features which were found to be HB3 devel-
opmentally regulated at any of the time-points 22-28 h
post infection were removed. For the 24 h drug
CQ 4 h
PN 24 h
CQ 24 h
PN 4 h
-3
-2
-1
0
1
Figure 2 All PN and CQ significant responsive features.T h e
data from 463 features showing significant changes in expression
identified from microarray analysis were clustered according to the
average gene expression changes as rows and the drug treatments
as columns. The colour key indicates the average log2 fold changes
in expression.
Table 1 Global Pearson correlations for microarray data
CQ 4 h CQ 24 h PN 4 h PN 24 h
CQ 4 h 1
CQ 24 h 0.62 1
PN 4 h 0.56 0.77 1
PN 24 h 0.62 0.73 0.65 1
Global Pearson correlation coefficients for each pairing of drug treatment
conditions were calculated from the 463 features significantly responsive to
PN and/or CQ.
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Figure 3 Correlation between K1 Trophozoite (22-24 h) and
intraerythrocytic developmental cycle data for strain HB3.
Kritsiriwuthinan et al. Malaria Journal 2011, 10:242
http://www.malariajournal.com/content/10/1/242
Page 5 of 10treatments, features developmentally regulated at any of
the HB3 time-points 22-48 h and 1-4 h post infection
were removed. This filtering, therefore, establishes a
subset of differentially expressed features in which fea-
tures showing expression changes solely due to differ-
ences in staging during the course of drug exposure
have been removed. In total, there were 145 features
after developmental filtering which showed significantly
different expression under at least one of the drug expo-
sure conditions tested (Additional file 5).
Developmental arrest induced by drug action is but
one confounding factor in the analysis of drug-induced
transcriptional profiles. In order to gain insight into
drug mechanism of action from microarray data, the
primary or direct effects of the drug need to separated
from indirect (e.g. general stress response), secondary
and bystander effects (reviewed in [38]). A recent P. fal-
ciparum microarray study identified a set of 3705 “per-
turbation” responsive genes which change expression in
response to widely different drugs and other stresses
[39]. The perturbation gene set was then used to filter
out features likely responding to drug in an indirect, or
secondary fashion. 72 PN/CQ responsive features with
gene annotations matching the perturbation gene list
were removed by this filtering step. Another indirect
genetic response to drug action is activation of gameto-
cyte stage genes [40]. 26 PN/CQ features with gene
annotations matching the list of genes up-regulated (p-
Anova < 0.05) in gametocyte stages [41] were removed
by this final filtering step, leaving 46 primary PN/CQ
responsive features. The heatmap analysis of these fea-
tures in Figure 4 shows overall similarity of PN and CQ
responses. Inspection of the annotated genes for these
features reveals a striking abundance of genes encoding
host-exported proteins of different families, i.e. var, ste-
vor, surfin, rifin and phist, which is supported by the sig-
nificant gene ontology terms (Table 2).
Discussion
Although PN is well-recognized as a highly potent anti-
malarial drug against both sensitive and multi-drug
resistant lines of malaria parasites, its molecular
mechanism of action is not fully understood. Previous
studies have demonstrated that its primary mode of
action is the same as CQ, namely interaction with haem
and subsequent inhibition of b-haematin assembly.
Given that both drugs are structurally related and are
proposed to act on the same target(s), it was hypothe-
sized that they may induce similar transcriptomic
changes at IC50 concentrations.
The transcriptome of chloroquine-resistant P. falci-
parum K1 strain in response to PN and CQ exposure
was investigated. Similar to previous microarray studies
of P. falciparum under anti-malarial drug treatment
[36,42], the magnitude of change in expression for most
genes in response to CQ and PN was low. Nonetheless,
297 features showed significant change to PN and 205
to CQ. The overlap of 40 features among the PN and
CQ features was highly significant, suggestive of a simi-
lar genetic response. In contrast, the PN and CQ fea-
tures overlapping with those responsive to an unrelated
drug, Pyrimethamine in the same K1 parasite strain
exposed for 24 hours were not significant. In total, 461
features showed significant changes in response to either
or both PN and CQ drugs. A major difficulty in inter-
preting these data with respect to primary mechanism
of drug action is confounding responses not directly
related to the mechanism of drug action. Although no
delay of parasite development was observed in CQ and
PN drug-treated cultures by comparison of morphology,
it is known that transcriptional arrest precedes morpho-
logical arrest [37]. It should be noted that the term tran-
scriptional arrest relates to a delay in the stage-specific
pattern of gene expression within a short time-frame, i.
e. the same 48 h developmental cycle. This phenomenon
is probably quite distinct from the changes occurring in
recrudescing parasites in the longer time-scale of a clini-
cal treatment period (3-4 days). Such a delay in the
developmental programme of gene expression may,
therefore, have a confounding effect on identification of
drug-specific responders. A conservative approach was
taken to address this confounding effect, in which all
stage-specific transcripts from the corresponding devel-
opmental stages during the different drug treatment per-
iods were removed. This approach, however, could lead
to removal of genes which are primary drug responsive,
yet developmentally regulated.
Besides the primary effects of PN and CQ treatment, i.
e. inhibition of a-haematin formation and glutathione-
dependent haem degradation, secondary/downstream
effects of these drugs on the parasite have been
described. At very high concentrations, CQ and other
quinoline drugs disrupt vesicular transport [43,44].
Moreover, CQ inhibits translation [45], disrupts mito-
chondrial membrane potential and induces DNA frag-
mentation [46]. The PN and CQ responsive microarray
features with gene annotations matching the perturba-
tion dataset [39] could be considered secondary
responses. The gene annotations encompass a variety of
cellular functions, although none are significantly asso-
ciated with the aforementioned CQ secondary effects.
Microarray features corresponding to the Pfcrt gene,
which mediates resistance to CQ, showed significant
changes in expression in response to PN and CQ. How-
ever, the Pfcrt gene is present in the perturbation data-
set and cannot be considered as a primary PN or CQ
responsive gene. Moreover, no significant changes in
expression were found for features corresponding to
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in the literature (Pfmdr1, Pfmdr 2, Pfmrp1, Pfmrp2 and
Pfnhe1).
After filtering by comparison with the perturbation
dataset and removal of genes known to be up-regulated
in gametogenesis, the remaining 46 PN and CQ
responsive features showed a significant over-representa-
tion of genes encoding host-exported proteins. These
genes belong to large gene families, including var, stevor,
surfin, rifin and phist. A previous study of the transcrip-
tional response of P. falciparum under IC50 CQ treat-
ment showed that 36 genes could be considered as
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pMAL8P1.147_20
Ppla_ORF101_110
J206_7
pPF10_0134_457
I1136_2
pPF11_0005_9
M28249_5
I8058_1
F11007_3
pPF14_0163_33
N170_4
A14801_37
A4732_19
D51731_2
D42243_7
D6287_62
pPFE1190c_105
E20260_6
F41817_1
oPFF72436
F6919_1
pMAL6P1.163_2486
pMAL6P1.162_5
pMAL6P1.124_55
pMAL6P1.120_638
J1249_1
F55150_2
oPFL0032
oPFL0031
Prps19
Ppla_tRNA−Ala_1
Ppla_tRNA−ArgPrime2
PtRNA−His
Ppla_tRNA−Ile
PtRNA−Phe
PtRNA−Ser2
PtRNA−Ser
PtRNA−Thr
Ppla_tRNA−Val_2
PN 4 h
CQ 4 h
CQ 24 h
PN 24 h
var (erythrocyte membrane protein 1)
conserved Plasmodium protein, unknown function
dynein light chain
phist-b
surfin pseudogene
var (erythrocyte membrane protein 1)
phist-a
var (erythrocyte membrane protein 1)
var (erythrocyte membrane protein 1)
reticulocyte binding protein 2 homologue a
var (erythrocyte membrane protein 1)
rifin
rifin
plastid
surfin 8.1
plastid
syntaxin Qa-SNARE
plastid
plastid
plastid
plastid
plastid
plastid
rifin
plastid
f-actin capping protein alpha subunit
stevor
plastid
rifin
not annotated
plastid
rifin
rifin
Oligo ID Annotated ORF
-0.5
0
-1.0
-1.5
0.5
1.0
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
conserved Plasmodium protein, unknown function
Figure 4 PN and CQ responsive features after filtering of developmental and secondary responsive features. The data from 46 features
which show significant changes in expression under CQ and/or PN exposure after filtering identified from microarray were clustered according
to the average gene expression changes as rows and the drug treatments as columns. The colour key indicates the log2 fold changes in
expression. The feature oligo IDs and gene annotations (Plasmodb v8.0) are shown on the right.
Table 2 Enriched Gene ontology terms represented by the 46 PN/CQ features after filtering
GO ID Ontology Term q m T K genes log_odds_ratio p
GO:0005576 cellular_component extracellular
region
7 221 2198 10 PFA0765c//MAL7P1.57//PFE0065w//PFI0005w//
PFF0855c//PFL2640c//PFL2620w
2.7995 0.000272
GO:0018995 cellular_component host 7 220 2198 10 PFA0765c//MAL7P1.57//PFE0065w//PFI0005w//
PFF0855c//PFL2640c//PFL2620w
2.806043 0.000272
GO:0020002 cellular_component host cell plasma
membrane
5 190 2198 10 PFA0765c//MAL7P1.57//PFI0005w//PFF0855c//
PFL2640c
2.53212 0.01505
GO:0033643 cellular_component host cell part 7 220 2198 10 PFA0765c//MAL7P1.57//PFE0065w//PFI0005w//
PFF0855c//PFL2640c//PFL2620w
2.806043 0.000272
Significantly enriched gene ontology terms were identified using the GOEAST tool. The top four significant terms are shown. GO ID is the identifier for the GO
term in the Gene Ontology Project, Ontology represents the ontology category the GO term belongs to, term is the GO definition, q is the number of genes
associated with the same GO ID in the data analyzed, m is the total number of genes associated with the listed GO ID in the genome, t is the total number of
annotated genes for Plasmodium falciparum, k is the total number of features with gene annotations considered for analysis, genes are the Gene IDs sharing the
same significant GO ID, log_odds_ratio is the log2 odds ratio of the GO ID enrichment and p is the FDR-adjusted p-value for significance.
Kritsiriwuthinan et al. Malaria Journal 2011, 10:242
http://www.malariajournal.com/content/10/1/242
Page 7 of 10primary CQ responsive, with many more genes showing
changes in expression because of differences in staging
and secondary effects [47]. Of the 36 primary CQ genes
reported in [47], two rifin genes (PF10_0006 and
PF10_0404) are also present among the annotated genes
represented by the 46 PN/CQ responsive features after
filtering. Although the data are suggestive of primary
PN and CQ responsive genes, other perturbations such
as antifolates [36], and the bisthiazolium compound T4
[40] also induce changes in expression of host-exported
proteins of multi-gene families, albeit for separate genes.
Despite some common features of transcriptional regu-
lation, including epigenetic switching mechanisms and
sharing of transcriptional activators [48], very little is
known of how the expressions of these gene families are
modulated by environmental perturbation. Given that
different drugs exert responses in these gene families,
their roles as potential mediators of drug resistance
should be investigated further.
Comparison of the drug-responsive genes shows that
PN appears to exert a faster-acting transcriptional per-
turbation than CQ. From the four drug treatment con-
ditions tested in this study, the PN 4 h treatment was
globally more similar to the CQ 24 h treatment than
CQ 4 h. Similarities between the PN and CQ transcrip-
tional responses were also noted in overlapping genes
and functional categories, which support the hypothesis
that the genes responsive to the two drugs are similar.
It should be noted that because PN is far more potent
than CQ against the K1 strain, much higher concentra-
tions of the latter drug were needed to produce similar
biological effects. Therefore, the differences in cytosolic
concentrations between PN and CQ may contribute to
some of the minor observed differences between the
PN and CQ transcriptional responses. A simple expla-
nation for why PN is faster acting and thus more effec-
tive than CQ, especially against CQ-resistant parasites,
can be made based on the known chemical properties.
PN is more hydrophobic than CQ, with a log P value
comparable to amodiaquine [49,50] and thus the
uptake into the food vacuole, the site of action, will be
faster for PN. Furthermore, PN has an extra highly
basic group, which means it may be protonated more
readily and thus accumulate more rapidly in the food
vacuole than CQ.
Conclusions
This study is the first to report global perturbations on
P. falciparum gene expression in response to IC50 con-
centration of PN. Since the primary modes of action for
PN and CQ are thought to be the same, expression
changes induced by CQ were studied for comparison.
The genetic response to PN and CQ are similar,
although PN appears to exert a faster and more
pronounced effect than CQ since the transcriptomic
changes are discernable after a 4 h exposure of PN,
whereas a longer exposure is needed for a comparable
effect with CQ. It is not possible, however, to relate the
drug-responsive genes with the mode of action of these
drugs, since the majority of genes changing expression
can be related with drug-induced developmental arrest
and general response to perturbation.
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